Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19196834 | PREPARATION METHOD OF N-BUTENYL AMIDE COMPOUNDS | May 2025 | August 2025 | Allow | 4 | 1 | 0 | No | No |
| 19079199 | METHOD OF TREATING EXCESSIVE SLEEPINESS AND/OR CATAPLEXY USING N-{2-(([1,1'-BIPHENYL]-3-YL)METHYL)PYRROLIDIN-3-YL}SULFONAMIDE DERIVATIVES | March 2025 | July 2025 | Allow | 4 | 1 | 0 | No | No |
| 18985731 | Compounds with nematicidal activity to pinewood nematode Bursaphelenchus xylophilus | December 2024 | May 2025 | Allow | 5 | 0 | 0 | Yes | No |
| 18799706 | PYRAZOLE AND IMIDAZOLE DERIVATIVES, COMPOSITIONS AND METHODS AS OREXIN ANTAGONISTS | August 2024 | February 2025 | Allow | 6 | 2 | 1 | Yes | No |
| 18750852 | SYNTHESIS OF CANNABINOIDS AND CANNABINOID PRECURSORS, AND RELATED COMPOUNDS, FORMULATIONS, AND METHODS OF USE | June 2024 | December 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18657828 | Method melt crystallization for preparing high-purity glabridin | May 2024 | January 2025 | Allow | 9 | 1 | 0 | No | No |
| 18590187 | AKT1 MODULATORS | February 2024 | November 2024 | Allow | 8 | 1 | 0 | No | No |
| 18439523 | COMPOSITIONS AND METHODS FOR TREATING RETINAL DEGRADATION | February 2024 | July 2024 | Allow | 5 | 1 | 0 | No | No |
| 18493380 | 4-(4,5-BIS(4-BROMOPHENYL)-2-PHENYL-1H-IMIDAZOL-1-YL)BENZOIC ACID AS AN ANTIMICROBIAL COMPOUND | October 2023 | February 2024 | Allow | 4 | 1 | 0 | No | No |
| 18375929 | 2'-ALKYLOXY-6'-PHENYL[3,4'-BIPYRIDINE]-3'-CARBONITRILE AS AN INSECTICIDAL AGENT AGAINST APHIS CRACCIVORA | October 2023 | January 2024 | Allow | 4 | 0 | 0 | Yes | No |
| 18474848 | AKT1 MODULATORS | September 2023 | February 2024 | Allow | 4 | 1 | 1 | Yes | No |
| 18459890 | STRIGOLACTONE DERIVATIVES | September 2023 | March 2025 | Abandon | 19 | 0 | 1 | No | No |
| 18193299 | MANIPULATING HYDROPHILICITY OF CONVENTIONAL DYE MOLECULES FOR TRACER APPLICATIONS | March 2023 | December 2024 | Allow | 21 | 1 | 1 | Yes | No |
| 18009440 | DIMETHYLSULFOXIMINE DERIVATIVE | December 2022 | August 2025 | Allow | 32 | 0 | 0 | No | No |
| 17965352 | 3-Methylideneoxan-4-One Compounds and Substituted Derivates Thereof as Inhibitors of Telomerase | October 2022 | April 2025 | Allow | 30 | 1 | 1 | Yes | No |
| 17964168 | CONJUGATION METHODS | October 2022 | March 2025 | Abandon | 29 | 1 | 0 | No | No |
| 18045276 | PESTICIDALLY ACTIVE THIOPHENE DERIVATIVES | October 2022 | January 2025 | Abandon | 27 | 1 | 0 | No | No |
| 17961978 | PROCESS FOR PRODUCING 5-ARYL-1H-PYROLLE-3-CARBONITRILE COMPOUNDS BY DEHALOGENATION | October 2022 | March 2025 | Allow | 29 | 1 | 1 | No | No |
| 17936308 | METHODS FOR CONVERTING THC-RICH CANNABINOID MIXTURES INTO CBN-RICH CANNABINOID MIXTURES | September 2022 | December 2024 | Abandon | 27 | 1 | 0 | No | No |
| 17940199 | BRIGHT TARGETABLE RED CA2+ INDICATORS | September 2022 | July 2024 | Allow | 23 | 1 | 0 | Yes | No |
| 17899297 | ANTI-CANCER COMPOUNDS | August 2022 | November 2023 | Allow | 14 | 0 | 0 | Yes | No |
| 17823053 | Simplified Structural Mimetics of AIPS as Quorum Sensing Inhibitors | August 2022 | July 2024 | Allow | 22 | 1 | 0 | Yes | No |
| 17885883 | CRYSTALLINE FORMS OF TENOFOVIR ALAFENAMIDE | August 2022 | December 2023 | Allow | 16 | 0 | 0 | Yes | No |
| 17869116 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | July 2022 | November 2024 | Allow | 28 | 2 | 1 | Yes | No |
| 17811880 | 4,9-DIOXO-4,9-DIHYDRONAPHTHO[2,3-B]FURAN-3-CARBOXAMIDE DERIVATIVES AND USES THEREOF FOR TREATING PROLIFERATIVE DISEASES AND INFECTIOUS DISEASES | July 2022 | November 2023 | Allow | 16 | 0 | 0 | Yes | No |
| 17857497 | PROCESSES FOR PREPARATION OF DAPAGLIFLOZIN OR ITS SOLVATES OR CO-CRYSTALS THEREOF | July 2022 | April 2024 | Allow | 22 | 1 | 0 | No | No |
| 17778282 | PROCESS FOR PREPARING CHROMAN COMPOUNDS | May 2022 | July 2025 | Allow | 38 | 1 | 1 | Yes | No |
| 17741366 | COMPOSITIONS AND METHODS COMPRISING SUBSTITUTED 2-AMINOIMIDAZOLES | May 2022 | March 2024 | Abandon | 22 | 1 | 0 | No | No |
| 17773231 | FLUORINE-CONTAINING PYRIMIDINE COMPOUND AND METHOD FOR PRODUCING SAME | April 2022 | March 2025 | Allow | 34 | 0 | 0 | No | No |
| 17660886 | DERIVATIVES OF KORORMICIN USEFUL AS ANTIBIOTICS | April 2022 | February 2024 | Allow | 22 | 1 | 0 | No | No |
| 17681634 | DEUTERATED SECNIDAZOLE FOR USE IN THE TREATMENT OF BACTERIAL VAGINOSIS AND METHODS AND USES THEREOF | February 2022 | August 2024 | Allow | 29 | 2 | 0 | Yes | No |
| 17668209 | COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) INHIBITORS | February 2022 | April 2024 | Abandon | 26 | 1 | 1 | No | No |
| 17577972 | Substituted Fused Pyrrolo-Diazepinones and Uses Thereof | January 2022 | October 2024 | Allow | 33 | 3 | 0 | Yes | No |
| 17536899 | Spiro Bicyclic Inhibitors Of Menin-MLL Interaction | November 2021 | February 2024 | Allow | 27 | 2 | 1 | No | No |
| 17612712 | COMPOSITION USING 4',6,7-TRIMETHOXYISOFLAVONE AND CATECHOL FOR MANAGING PULMONARY FIBROSIS | November 2021 | February 2025 | Allow | 39 | 1 | 0 | No | No |
| 17595533 | SUBSTITUTED FUSED BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN MEDICINES | November 2021 | May 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17528805 | SYSTEM AND METHOD FOR THE EXTRACTION OF ISOFLAVONES FROM SOYBEANS | November 2021 | July 2024 | Abandon | 32 | 2 | 1 | No | No |
| 17513491 | METHOD FOR TREATING INTERSTITIAL LUNG DISEASE | October 2021 | April 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17605962 | 3-AMINO-4H-BENZO[E][1,2,4]THIADIAZINE 1,1-DIOXIDE DERIVATIVES AS INHIBITORS OF MRGX2 | October 2021 | December 2024 | Allow | 38 | 1 | 0 | Yes | No |
| 17601536 | DEGRADERS OF KELCH-LIKE ECH-ASSOCIATED PROTEIN 1 (KEAP1) | October 2021 | February 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17486421 | POLYMORPHIC FORM OF SEPIAPTERIN | September 2021 | February 2025 | Allow | 40 | 4 | 0 | Yes | No |
| 17439061 | BENZOAZEPINE COMPOUND-CONTAINING PHARMACEUTICAL COMPOSITION | September 2021 | January 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17369088 | DIARYLUREAS AS CB1 ALLOSTERIC MODULATORS | July 2021 | April 2025 | Allow | 45 | 6 | 1 | Yes | No |
| 17322521 | SYNTHESIS OF 6-OXO-1,4,5,6-TETRAHYDROPYRIDIZIN-3-CARBOXYLIC ACID | May 2021 | October 2023 | Allow | 29 | 2 | 0 | Yes | No |
| 17285866 | METHOD FOR EFFICIENT EXTRACTION OF PLANT ANTHOCYANIDIN | April 2021 | April 2025 | Abandon | 48 | 4 | 0 | No | No |
| 17202951 | CINNAMALDEHYDE DERIVATIVE COMPOUNDS AND METHODS OF USE FOR NICOTINE CESSATION | March 2021 | August 2024 | Abandon | 41 | 4 | 1 | Yes | No |
| 17189870 | Compositions and Methods for Treating Multiple Sclerosis | March 2021 | March 2024 | Allow | 36 | 4 | 0 | Yes | No |
| 17189833 | Compositions and Methods for Treating Alzheimer's Disease | March 2021 | March 2024 | Abandon | 36 | 3 | 0 | Yes | No |
| 17262207 | METHOD FOR DECOMPOSING FLAVONOID GLYCOSIDE AND METHOD FOR PRODUCING FLAVONOID | January 2021 | September 2024 | Allow | 43 | 2 | 1 | No | No |
| 17050129 | Method for improving nucleation of crystals from solution | October 2020 | February 2024 | Abandon | 40 | 3 | 0 | No | No |
| 16936218 | ANTIMICROBIAL COMPOSITIONS FOR SURGICAL APPLICATIONS | July 2020 | March 2024 | Abandon | 43 | 1 | 0 | No | No |
| 16957880 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME | June 2020 | September 2024 | Abandon | 51 | 4 | 1 | Yes | No |
| 15733301 | COMPOUND FOR ORGANIC ELECTRIC ELEMENT, ORGANIC ELECTRIC ELEMENT COMPRISING THE SAME, AND ELECTRONIC DEVICE THEREOF | June 2020 | August 2024 | Allow | 50 | 4 | 1 | No | No |
| 16740167 | AMINONAPTHOQUINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR BLOCKING UBIQUITINATION-PROTEASOME SYSTEM IN DISEASES | January 2020 | October 2023 | Allow | 45 | 2 | 1 | No | No |
| 16626634 | ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME | December 2019 | April 2025 | Allow | 60 | 6 | 1 | Yes | No |
| 16668876 | THERMALLY ACTIVATED DELAYED FLUORESCENCE CHROMOPHORES AND ORGANIC LAYERS INCLUDING THE SAME | October 2019 | August 2024 | Allow | 58 | 4 | 1 | Yes | No |
| 16656284 | SELECTIVE SHIP INHIBITORS FOR TREATING DISEASE | October 2019 | May 2022 | Abandon | 31 | 2 | 1 | Yes | No |
| 16455038 | NEAR-IR GLUCOSE SENSORS | June 2019 | November 2024 | Allow | 60 | 4 | 0 | Yes | No |
| 11909623 | Use of Levo-Ornidazole For Preparing Anti-Parasitic Infection Drug | November 2007 | August 2017 | Abandon | 60 | 20 | 0 | Yes | Yes |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner RODRIGUEZ-GARCIA, VALERIE.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner RODRIGUEZ-GARCIA, VALERIE works in Art Unit 1759 and has examined 26 patent applications in our dataset. With an allowance rate of 50.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 41 months.
Examiner RODRIGUEZ-GARCIA, VALERIE's allowance rate of 50.0% places them in the 12% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by RODRIGUEZ-GARCIA, VALERIE receive 3.35 office actions before reaching final disposition. This places the examiner in the 92% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by RODRIGUEZ-GARCIA, VALERIE is 41 months. This places the examiner in the 20% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +23.1% benefit to allowance rate for applications examined by RODRIGUEZ-GARCIA, VALERIE. This interview benefit is in the 69% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 9.4% of applications are subsequently allowed. This success rate is in the 4% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 53.8% of cases where such amendments are filed. This entry rate is in the 80% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants file petitions regarding this examiner's actions, 40.0% are granted (fully or in part). This grant rate is in the 29% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 6% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 7% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.